Company news
Valirx Plc (LSE:VAL) news
Valirx Plc news releases on 6ix. Latest, Sep 15, 2026: Half-year Financial Report
Press releases & updates
Half-year Financial Report
September 15, 2026
Cytolytix Patent Update
August 10, 2026
Result of AGM, Warrants & Directorate Change
July 17, 2026
Conclusion of Evaluation with University of Dundee
June 22, 2026
Conclusion of Evaluation with Stingray
June 2, 2026
ValiRx Exercises Option on Evaluation Asset
June 1, 2026
Cytolytix Patent Granted
May 27, 2026
Result of Oversubscribed WRAP Retail Offer
May 21, 2026
WRAP Retail Offer for up to £150,000
May 18, 2026
Fundraising of up to £1,155,000
May 15, 2026
Change of Registered Office
March 31, 2026
ValiRx Commercial Update Q1 2026
March 26, 2026
ValiRx and TwinEdge to present Digital Twin data
March 24, 2026
ValiRx forms ValiRx Animal Health Ltd subsidiary
March 2, 2026
Exercise of Warrants
January 19, 2026
Replacement: Evaluation and Transfer Agreement
January 9, 2026
New Evaluation and Material Transfer Agreement
January 9, 2026
Holding(s) in Company
January 8, 2026
Result of GM & Issue of Equity
November 20, 2025
Posting of Circular and Notice of General Meeting
November 4, 2025
Result of WRAP Retail Offer
November 4, 2025
WRAP Retail Offer for up to £300,000
October 30, 2025
Fundraising of up to £1,050,000
October 30, 2025
Inaphaea Commercial update
October 14, 2025
Half-year Report
September 29, 2025
Inaphaea Commercial Update
September 18, 2025
Cytolytix Commercial update
September 1, 2025
Commercial update
August 26, 2025
ValiRx Awarded Grant from Open University
August 7, 2025
Update on Evaluation Agreement with Stingray Bio
August 5, 2025
Licensing Agreement with Dominion Biotech Ltd
August 4, 2025
Collaboration Agreement with Voxcell BioInnovation
July 29, 2025
Result of AGM
June 30, 2025
Ambrose Exercise Option on VAL401
June 20, 2025
ValiRx Investor Webinar
June 9, 2025
Final Results & Notice of AGM
June 6, 2025
Inaphaea Deal Extension With Dominion
May 12, 2025
Commercial Update
April 30, 2025
Termination of Letter of Intent with TheoremRx
April 3, 2025
Directorate Changes and new Advisory Board
March 27, 2025
Director Disclosure Update
March 21, 2025
Conclusion of Evaluation Project
February 24, 2025
Inaphaea Evaluation and Commercial Use Agreement
February 3, 2025
Extension of Evaluation Agreement
January 30, 2025
New Evaluation and Option Agreement
January 29, 2025
Update on proposed sub-license of VAL201
December 31, 2024
Result of GM, Issue of Equity, Warrants and TVR
December 30, 2024
ValiRx launches new interactive investor website
December 20, 2024
Broker Offer Results & Director/PDMR Subscription
December 10, 2024
Conditional Fundraising & Launch of Broker Offer
December 9, 2024